Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Traws Pharma ( (TRAW) ) is now available.
On June 3, 2025, Traws Pharma announced the publication of clinical efficacy data for patients with recessive dystrophic epidermolysis bullosa associated with locally advanced or metastatic squamous cell carcinoma treated with rigosertib. The Phase 2 study showed an overall response rate of 80% and complete responses in 50% of evaluable patients, highlighting significant potential for rigosertib in addressing this high unmet medical need.
The most recent analyst rating on (TRAW) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Traws Pharma stock, see the TRAW Stock Forecast page.
Spark’s Take on TRAW Stock
According to Spark, TipRanks’ AI Analyst, TRAW is a Underperform.
Traws Pharma’s overall stock score is low due to significant financial challenges and bearish technical indicators. However, recent corporate events, including positive trial data and new financing, provide a glimmer of hope for future improvements, albeit with high risk.
To see Spark’s full report on TRAW stock, click here.
More about Traws Pharma
Traws Pharma, Inc. operates in the pharmaceutical industry, focusing on oncology programs. The company is involved in the development of treatments for various cancers, with a particular emphasis on its legacy oncology programs, rigosertib and narazaciclib.
Average Trading Volume: 99,356
Technical Sentiment Signal: Sell
Current Market Cap: $7.9M
Learn more about TRAW stock on TipRanks’ Stock Analysis page.